ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50 Day Moving Average - Should You Sell?

Key Points

• ProQR briefly crossed above its 50-day moving average ($1.68) during Friday trading but last traded at $1.55, with a 200-day MA of $1.96 and volume around 1.15 million shares.
• Analysts are generally positive: MarketBeat shows a consensus rating of “Moderate Buy” (six Buys, one Hold, one Sell) and a consensus price target of $6.80, with individual targets ranging up to $9.
• The company remains unprofitable—Q1 EPS of ($0.09) missed estimates and revenue of $5.53M fell short—ProQR has negative margins and a market cap near $163 million.

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report)'s share price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.68 and traded as high as $1.68. ProQR Therapeutics shares last traded at $1.55, with a volume of 1,146,255 shares trading hands.

Analysts Set New Price Targets

PRQR has been the topic of several research analyst reports. Oppenheimer initiated coverage on ProQR Therapeutics in a research report on Thursday, March 12th. They set an "outperform" rating and a $9.00 target price on the stock. Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday, April 9th. Weiss Ratings restated a "sell (d-)" rating on shares of ProQR Therapeutics in a research report on Tuesday. Wall Street Zen raised ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday, March 14th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of ProQR Therapeutics in a research note on Friday, March 13th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.80.

ProQR Therapeutics Stock Performance

The business has a 50 day moving average of $1.68 and a two-hundred day moving average of $1.96. The firm has a market capitalization of $163.31 million, a price-to-earnings ratio of -3.37 and a beta of 0.10.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.The firm had revenue of $5.53 million for the quarter, compared to analyst estimates of $6.12 million. On average, equities analysts predict that ProQR Therapeutics N.V. will post -0.53 EPS for the current fiscal year.

Institutional Trading of ProQR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Privium Fund Management B.V. raised its stake in shares of ProQR Therapeutics by 7.2% in the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company's stock worth $10,823,000 after purchasing an additional 359,475 shares during the last quarter. Aberdeen Group plc raised its stake in shares of ProQR Therapeutics by 28.4% in the fourth quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company's stock worth $5,960,000 after purchasing an additional 651,853 shares during the last quarter. Ikarian Capital LLC raised its stake in shares of ProQR Therapeutics by 67.2% in the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company's stock worth $3,014,000 after purchasing an additional 600,000 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its stake in shares of ProQR Therapeutics by 3.9% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,246,234 shares of the biopharmaceutical company's stock worth $2,654,000 after purchasing an additional 46,596 shares during the last quarter. Finally, Citadel Advisors LLC raised its stake in shares of ProQR Therapeutics by 73.2% in the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company's stock worth $1,399,000 after purchasing an additional 277,749 shares during the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.